JACC:阿哌沙班剂量调整对药理学和临床预后的影响

2020-03-15 MedSci原创 MedSci原创

本研究的目的是描述阿哌沙班剂量调整对临床和药理学结果的影响。

本研究的目的是描述阿哌沙班剂量调整对临床和药理学结果的影响。

本研究纳入分析了ARISTOTLE临床试验中的18073名房颤患者,接受阿哌沙班2.5mg每日两次的患者的阿哌沙班暴露量要比接受标准剂量(5mg每日两次)要更少(p < 0.0001),在剂量调整的患者中(n=751),D二聚体和凝血酶原片段1+2(PF1+2)的减少与接受标准剂量的患者相似,且该类患者的卒中、大出血和全因死亡风险要高于接受标准剂量的患者。

研究结果显示,接受阿哌沙班2.5mg每日两次患者的血浆阿哌沙班浓度要低于接受5mg每日两次的患者,但是在有效性方面与标准剂量无明显差异。

原始出处:

Michel Z et al.Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.JACC.2020 Mar.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854688, encodeId=d8a51854688ee, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 19 14:28:30 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326519, encodeId=fadb132651956, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516188, encodeId=18f5151618877, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534745, encodeId=4d011534e4578, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380522, encodeId=d876380522cb, content=刊编文医论anni30138, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 18:07:28 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-07-19 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854688, encodeId=d8a51854688ee, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 19 14:28:30 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326519, encodeId=fadb132651956, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516188, encodeId=18f5151618877, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534745, encodeId=4d011534e4578, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380522, encodeId=d876380522cb, content=刊编文医论anni30138, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 18:07:28 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854688, encodeId=d8a51854688ee, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 19 14:28:30 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326519, encodeId=fadb132651956, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516188, encodeId=18f5151618877, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534745, encodeId=4d011534e4578, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380522, encodeId=d876380522cb, content=刊编文医论anni30138, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 18:07:28 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854688, encodeId=d8a51854688ee, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 19 14:28:30 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326519, encodeId=fadb132651956, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516188, encodeId=18f5151618877, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534745, encodeId=4d011534e4578, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380522, encodeId=d876380522cb, content=刊编文医论anni30138, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 18:07:28 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854688, encodeId=d8a51854688ee, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Jul 19 14:28:30 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326519, encodeId=fadb132651956, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516188, encodeId=18f5151618877, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534745, encodeId=4d011534e4578, content=<a href='/topic/show?id=6be9230842e' target=_blank style='color:#2F92EE;'>#临床预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23084, encryptionId=6be9230842e, topicName=临床预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a72412536387, createdName=budeshao, createdTime=Tue Mar 17 02:28:30 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380522, encodeId=d876380522cb, content=刊编文医论anni30138, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 18:07:28 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 xcdnxj

    刊编文医论anni30138

    0

相关资讯

JACC:心肌炎患者的室性心律失常研究

心肌炎患者不同时期的室性心律失常(VAs)尚未得到系统的研究。本研究的目的是比较活动性心肌炎(AM)与既往心肌炎(PM)患者VAs的基线和随访临床特征。

JACC:即时高敏肌钙蛋白检测试剂盒对疑似心梗具有较好的诊断价值

目前,高敏肌钙蛋白(hs-cTn)试剂盒检测多用于医院大型实验平台。本研究旨在评估即时hs-cTn检测试剂盒(POC-hs-cTn)对心梗疑似患者的诊断价值。

Heart:强化动机式访谈干预对心血管高风险人群无明显效果

肥胖的流行正导致心血管疾病高危人群的患病率不断上升,进而否定了降低心血管疾病死亡率的医学进展。本研究目的旨在评估评估减轻心血管病高危患者的体重和增加体力活动强化生活方式干预的临床效果和成本效益。

JACC:liraglutide对2型糖尿病患者心血管的影响

本研究的目的旨在评估胰高血糖素样肽-1受体激动剂liraglutide对LEADER临床试验中患者的心血管事件发生和死亡率的影响。

盘点:JACC3月第二期研究一览

1. 睡眠不规律是心血管疾病的独立危险因素

JACC:三尖瓣手术可降低成年先心病术后患者反流程度

三尖瓣返流(TR)在成人因法洛四联症(TOF)或肺动脉狭窄(PS)而需要肺动脉瓣置换术(PVR)的患者中很常见,本研究的目的旨在评估三尖瓣手术对先心病术后患者预后的影响。